 |
| |
| Sinerem® is the brand name (same as Combidex®) for an ultrasmall superparamagnetic iron oxide ( USPIO) to detect metastatic disease in lymph nodes. Metastatic nodes show less uptake of this MRI contrast agent, which results in less signal decrease and allows the differentiation of normal lymph nodes from normal-sized, metastatic nodes.
Lymph node imaging with Sinerem® is performed 24 to 36 hours after slow infusion. Normal lymph nodes turn black post contrast, namely on T2* weighted images. Metastatic lymph nodes remain unchanged in signal intensity.
Indication and Diseases: Cancer, Imaging for diagnosis, Lymphatic disorders.
See Ferumoxtran, and Classifications, Characteristics, etc.
Guerbet decided in 2007 to withdraw its Marketing Authorisation Application
(MAA) for Sinerem.Drug Information and Specification r1=25, r2=160, B0=0.47T, r1=23.3, r2=48.9, B0=0.47T PHARMACOKINETIC Vascular, lymph v. hepatocyte (AG-USPIO) PREPARATION Suspend in an isotonic glucose solution DO NOT RELY ON THE INFORMATION PROVIDED HERE, THEY ARE
NOT A SUBSTITUTE FOR THE ACCOMPANYING PACKAGE INSERT! | |
 |
|
• View the DATABASE results for 'Sinerem®' (6).
| |
| | |  Further Reading: | | Basics:
|
|
News & More:
| |
| |
previous
(.pdf)
top
